Cytokinetics, Incorporated Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
(Thomson Reuters ONE) -
South San Francisco, CA - December 18, 2012 - Cytokinetics, Incorporated
(NASDAQ: CYTK), announced today that NASDAQ has approved the Company's request
to voluntarily transfer the listing of its shares of common stock from The
NASDAQ Global Market to The NASDAQ Capital Market. The transfer will be
effective at the opening of business on December 20, 2012 and the Company's
common stock will continue to trade under the symbol "CYTK".
As previously reported, on June 18, 2012, NASDAQ notified the Company that its
listed security no longer met the minimum $1.00 bid price per share requirement,
and subsequently the Company was unable to regain compliance within the 180
calendar day period provided. NASDAQ has determined, however, that upon
transfer to The NASDAQ Capital Market, the Company is eligible for an additional
180 calendar day period, or until June 17, 2013, to meet the minimum $1.00 bid
price per share requirement. If at any time during this additional time period
the closing bid price of the Company's security is at least $1.00 per share for
a minimum of 10 consecutive business days, the Company will be in compliance
with the requirement and the matter will be closed.
The NASDAQ Capital Market is one of the three markets for NASDAQ-listed stock
and operates in the same manner as The NASDAQ Global Market. Companies listed
on The NASDAQ Capital Market must meet certain financial requirements and adhere
to NASDAQ's corporate governance standards.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment with tirasemtiv produced potentially clinically relevant
pharmacodynamic effects in Phase II trials. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to the properties and potential benefits of Cytokinetics'
drug candidates and potential drug candidates. Such statements are based on
management's current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory approval and
production of Cytokinetics' drug candidates and potential drug candidates that
could slow or prevent clinical development or product approval, including risks
that current and past results of clinical trials or preclinical studies may not
be indicative of future clinical trials results and that Cytokinetics' drug
candidates and potential drug candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy. For further information regarding
these and other risks related to Cytokinetics' business, investors should
consult Cytokinetics' filings with the Securities and Exchange Commission.
Contact:
Jodi L. Goldstein
Manager, Marketing & Corporate Communications
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1666146]
Unternehmensinformation / Kurzprofil:
Datum: 18.12.2012 - 22:03 Uhr
Sprache: Deutsch
News-ID 214161
Anzahl Zeichen: 5817
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics, Incorporated Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
